SUBJECT INDEX

abbreviations: CAPD continuous ambulatory peritoneal dialysis
HD haemodialysis
HLA human leucocyte antigen
PD peritoneal dialysis
PTH parathyroid hormone
RT renal transplantation

A and B matching
see HLA matching
ABO matching
see blood group matching
Abstracts
selection, EDTA conference, 747–752
Acceptance of new patients 1978, 12
Access, vascular
see Vascular access
Acetate
or bicarbonate in dialysate, 122–128
in dialysate and hypertriglyceridaemia, 115–121
Acid-base balance
and dialysate, 115–121
Acid therapy
for urinary stone disease, 556–565
Adriamycin-induced nephrotic syndrome
and platelet sensitivity, 493
Age
children on treatment 1978, 83
of patients 1978, 9–17
Albumin
and platelets in nephrotic syndrome, 587–495
Aldosterone concentration
plasma, and hypertension and captopril, 603–609
Alkaline phosphatase
and vitamin D, 637–644
Allograft
see Graft
Alport's syndrome
as primary renal disease, 19
Aluminium
accumulation in renal failure, 588–596
in chronic renal failure patients, 665–667
and dialysis dementia, 407–412
Aluminium (continued)
and dialysis encephalopathy, 659–660
and neurological problems in dialysis
patients, 663–664
Amiloride
for renal hypercalciuria, 571–576
Amino acids
in HD patients, 129–134
Aminoglycoside nephrotoxicity
diuretics and, 681–682
low molecular weight proteins and urinary
markers in, 597–602
Amyloidosis
classification, 501
dimethylsulphoxide to treat, 500–505
as primary renal disease, 19
and recovery of renal function, 43
Anaemia
from blood taking for biochemical
measurements, PD patients, 737–738
and haemofiltration, 218
renal
eythropoiesis in, 481–486
Analgesic nephropathy
see also Drug nephropathy and Drug
toxicity
prevention, 466–468, 474
Angiocardio graphic studies
in HD patients, 244–251
Angiography
or thermography for vascular access
survey in HD, 272–276
Angiotensin I and II
and captopril, 603–609
Antibodies
see also HLA matching, immunisation
anti-lymphocyte, post-transplant 1978, 63–64
Antibodies (continued)
cytotoxic
pre-transplant, 419–425
endothelial, in RT, 431–436
and graft survival, 356
HLA, immunisation against, 372–375
Antibody-induced suppression, 311–313
Anticoagulants
in dialysis, 135–140
heparin and prostacyclin in
haemoperfusion, 225–231
Antigen
see HLA, DLA
Antihistamines
and Heymann nephritis of rats, 706–708
Antithrombin III
and platelet sensitivity, 493
Arachidonic acid
and platelet sensitivity in nephrotic
syndrome, 487–495
Arginine vasopressin levels
in HD patients, 238–242
Arsenic
in chronic renal failure patients, 665–667
Arteriosclerosis
post-transplant and lipid disorders, 339
Artificial kidneys
see Dialysers
Aseptic necrosis
and hypophosphataemia, 622
post-transplant, 338
Atheromatous lesions
and lipid disorders, 339
atrophy, renal
familial, 542–550
Avascular necrosis
photon absorptiometry and radioisotope
technique to detect, 672–674
after renal transplantation, 332–338
Azathioprine
and graft survival, 388–394
and phosphate wasting, 624–629
with prednisolone for rejection, 395–400
Bismuth toxicity
and aluminium toxicity, 595
Blind patients
and CAPD, 184–185
Blood
access
see vascular access
flow
see Haemodynamic studies
group matching and graft survival,
301–302
Lewis system, and renal
transplantation, 377–382
pressure
see also Hypertension, hypotension,
vasopressin
control and CAPD, 190
in dialysis, 121, 127
in haemofiltration, 695–697
post-transplant, and PTH,
679–680
taking
for biochemical measurements in PD,
and anaemia, 727–728
transfusion
erthrocyte, and graft survival,
366–371
and graft survival, 300–301, 359–365, 400
HLA, immunisation against, and,
372–375
and Lewis compatibility, 377–382
pre-transplant 1978, 62–64, 71
and anaemia, 419–425
Body fluid balance
in dialysis, cardiothoracic ratio and,
692–694
Bone
see also Calcium
disease, renal 1978, 50–51
and aluminium, 588–598
avascular necrosis of bone after renal
transplantation, 332–338
children 1978, 93
vitamin D to treat, 644–648
and haemofiltration, 218–224
hormone secretion and, 649–655
photon absorptiometry to detect,
672–674
and propranolol, 668–671
radioisotope technique to detect,
672–674
steroids and, after renal transplantation,
332–338
and vitamin D
analogues to treat, 637–644
children, 644–648

Balkan nephropathy
as primary renal disease, 19
Berger's disease (IgA glomerulonephritis)
IgA levels in, 513–519
and HLA Bw35 antigen, 551–555
Bicarbonate
or acetate in dialysate, 122–128
in dialysate and hypertriglyceridaemia,
115–121
Biochemical measurements
value in CAPD, 737–738
Births, live 1978, 43–44

756
Bone (continued)
disease, renal and vitamin D (continued)
metabolism and, 630–636
metabolites and osteitis fibrosa,
675–676
marrow depression as cause of death 1978,
23–25
mineral and urinary tract stones, 563
Bradykinin and captopril, 603–609
Bromocriptine and prolactin, 700–702
Bumetanide and gentamicin nephrotoxicity,
681–682

Cachexia as cause of death 1978, 23–25
in children, 86
Cadaver graft
see Graft
Cadmium and renal disease, 468
Calcareaous nephrolithiasis in hypercalciuria,
721–722
Calcium
see also Bone disease, renal and
Hypercalciuria
content of hand and vitamin D, 642
excretion and hyperoxaluria, 569
parathyroid hormone, post-transplant,
and, 677–678, 679–680
in peritoneum in dialysis, 155
and stones, urinary tract, 556–565
and thiazide diuretics, 571–576
Calcitonin concentrations, propranolol and
metoprolol, 649–655
Calculus
see Stone
CAPD
see Peritoneal dialysis, continuous
ambulatory
Captopril
for hypertension, 603–609
in HD patients, 610–617
side effects, 614–615
Carcinoma, renal pelvic and analgesic
nephropathy, 467
Cardiac
see also Myocardial
arrest as cause of death 1978, 23–25
in children, 86
failure as cause of death 1978, 23–25
HD patients with, 244–251
function and PTFE grafts for HD,
266–271
index in PD patients, 165–170
Cardiographic studies in HD patients,
244–251
Cardiomegaly, HD patients with 244–251
Cardiothoracic ratio and body fluid balance
in dialysis, 692–694
Catheter function and CAPD, 191, 192, 193
Cells
see Memory cells, Suppressor cells, T cells
‘Centre effect’, 318–325
Centres
activity 1978, 9
children 1978, 80–83
variations in, 318–325
Cerebro-vascular accident
as cause of death 1978, 23–27, 29, 71
in children, 86
thrombosis and platelet sensitivity,
487–495
Cephalosporins and aminoglycosides,
proteinuria and, 597–602
Charcoal haemoperfusion
see haemoperfusion
Children
bone disease, renal in, 93, 644–648
continuous ambulatory peritoneal
dialysis for, 178, 183
dialysis and transplantation 1978
see contents, 75
growth
see Growth
screening for urinary infection, 459–462
Children’s ward in centres for children 1978,
81
Cholesterol
see lipid disorders
Chronic renal failure
see renal failure, chronic
Cimetidine
post-transplant 1978, 63–64
pre-transplant, 400
Cineangiography, left ventricular, in HD
patients, 244–251
Circulating immune complexes in primary
glomerulonephritis, 714–716
Complement breakdown products and
disease detection, 709–710
Conference, EDTA, programme selection,
747–752
Congenital disease
as primary renal disease 1978, 18
in children, 84
and recovery of function 1978, 43
renal tract abnormalities, 542–550
Continuous ambulatory peritoneal dialysis
see Peritoneal dialysis, continuous
ambulatory
Converting-enzyme inhibitor for hypertension,
603–609
Copper in chronic renal failure patients,
665–667
Coronary thrombosis
see Thrombosis, coronary
Cortical necrosis
as primary renal disease, 19
in children 1978, 84
recovery of renal function after, 44, 498
Corticosteroids
see Steroids
Creatinine levels and meat ingestion, 506–572
Cross matching
see HLA matching, blood group matching
Cryoglobulinemia
in Berger's disease, 578
plasma exchange in, 520–517
Cyclophosphamide for rejection, 388–394
Cyclosporin A
mechanism of action, 316
in renal cadaver grafting, 305–309, 316–317
side effects, 308
Cystic kidney disease
as primary renal disease 1978, 18
children, 84
and recovery of renal function, 43
Cystinosis as primary renal disease, 19
Cystometry and renal tract abnormalities, 542–550
Cytomegalovirus infection, cellular immunity and, in RT patients, 745–746
Cytostatic drugs and immune complex disease, 526
Cytotoxic antibodies, pre-transplant, 419–425
Cytotoxicity
see Immunosuppression, Renal transplantation, Rejection

D locus antigen
see HLA matching; DR matching
Data recording methods, EDTA, 5
Death rates
see also Patient survival
1978, 22–35, 71, 72
children 1978, 86–92
Dementia
as cause of death 1978, 23–25
dialysis
and aluminium, 407–412, 595, 663–664
and CAPD, 191
and RT, 407–412
Dermatological findings in RT patients, long-term, 741–742
Development
see Growth
Diabetes
hypertension and uraemic, 470
insulin in uraemic, 583–587
ketosis-susceptible, and peritoneal dialysis, 735–736

Diabetes (continued)
peptide hormones in uraemic, 583–587
peritoneal dialysis, and ketosis-susceptible, 735–736
peritoneal dialysis, continuous ambulatory, for renal failure in, 184–189, 190
as primary renal disease 1978, 18, 19
and recovery of function, 43
and re-transplantation, 350
vascular access in HD patients with, 54
Dialysate
acetate free bicarbonate buffered, 115–121
acetate or bicarbonate in, 122–128
for diabetics on CAPD, 188, 190
water preparation 1978, 57–59
Dialysers
characterisation, 287–288
high flux, 286–294
large surface area, acetate or bicarbonate in dialysate in, 122–128
selective dual filtration artificial kidney (SEDUFARK), 212–217
wearable filtration artificial kidney (WFAK), 205–211
Dialysis
see also Haemodialysis
age of patients 1978, 9
aluminium and neurological abnormalities, 663–664
cardiopulmonary ratio and body fluid balance, 692–694
centres, activity 1978, 9
children, 1978, 85–86
dementia
see Dementia, dialysis
encephalopathy, early detection, 659–660
fluid
see Dialysate
frequency 1978, 51
growth of children on 1978, 93–95
haemo-
see haemodialysis
haemofiltration
see haemofiltration
haemoperfusion
see haemoperfusion
hepatitis, new strain, in patients on, 141–147
home vs. hospital, death rates 1978, 22, 24, 71
index, 293
for middle molecules, 107–114
intolerance, haemofiltration for, 218–224
keto-analouges in patients on, 719–720
oxalate removal by, 717–718
Dialysis (continued)
peptide hormones and, 583–587
peritoneal,
see peritoneal dialysis
for prolonged acute renal failure, 498
recovery of function following 1978,
41–43
residual renal function and requirements,
107–114
schedules, short, and dialysis index for
middle molecules, 107–114
sexual activity in patients on prolactin
and zinc and, 661–662
techniques 1978, 51–59
children, 85–86
time on, prior to RT, 400
reduction, 107–114
ultrafiltration
see ultrafiltration
vitamin D therapy for children on,
644–648
Diet
amino acids in HD patients, 129–134
meat and creatinine levels, 506–512
Dietician in centres for children 1978, 81
1,25 dihydroxycholecalciferol
see vitamin D metabolites
Dimethylsulphoxide, amyloidosis, renal to
treat, 500–505
Disabling disease 1978, 44–48
children, 92–93
Disodium cromoglycate and Heymann
nephritis in rats, 706–708
Diuretics
thiazide, in renal hypercalciuria, 571–576
and gentamicin nephrotoxicity, 681–682
DLA matching and graft survival, 366–371
Donnan phenomenon, 204
Donor
see Graft
DR matching
see HLA matching
Drug metabolising enzymes, plasticisers and,
232–237
Drug nephropathy
algesic nephropathy, prevention,
466–468, 474
as primary renal disease 1978, 18
and recovery of renal function, 43
Drug toxicity as cause of death 1978, 23–25
Drugs
aluminium containing, toxicity, 588–596
aminoglycosides
see Aminoglycosides
anticoagulants, 135–140, 225–231
antihistamines and Heymann nephritis,
706–708
Drugs (continued)
anti-rheumatic, and amyloidosis, 500–505
converting-enzyme inhibitors, 603–609
diuretics, 571–576, 681–682
disodium cromoglycate, 706–708
H₂ receptor blocking, pre-transplant, 400
hepatotoxic, 146
hypotensive and hepatitis, 146
parathyroid hormone, 649–655
immunosuppressive
see Immunosuppression
penicillins, 597–602
steroid
see steroid drugs
Dysarthria and dialysis encephalopathy,
659–660
Dyslipaemia, post-transplant, 339–346
Dysplasia, renal, as primary renal disease in
children 1978, 84
Dysplastic kidneys, 542
 Dyspraxia and dialysis encephalopathy,
659–660
EDTA conference, programme selection,
747–752
Electroencephalogram and aluminium in
dialysis patients, 663–664
Elements, trace, in chronic renal failure
patients, 665–667
Embolus, pulmonary, as cause of death 1978,
23–25
Encephalopathy
aluminium and, 588–596
dialysis, early detection, 659–660
Endocrine
see Hormone
Endothelial antibodies in renal transplantation,
431–436
Enzymes, drug metabolising and plasticisers,
232–237
and memory cells, 437–441
and vitamin D, 637–644
Erythrocyte
hexose monophosphate shunt in uraemia,
475–480
organic phosphates in uraemia, 723–724
transfusions and graft survival, 366–371
Erythropoetin levels in uraemic patients,
481–486
Di-2-ethylhexylphthalate (DEHP) toxicity
and liver in uraemia, 232–237

Fabry’s disease, foetal liver transplant in,
413–418

759
Facilities of centres

*see* Centres

Familial disease

*see* Congenital disease

Femoral head necrosis, methylprednisolone and, 72

Ferritin and mesangial immunoglobulin, 535–541

Fever and thermography in RT, 386

Fibro-osteoclasia and vitamin D therapy, 644–648

Filtrate, uraemic toxicity, 216

Filtration-fraction and converting-enzyme inhibitor for hypertension, 603–609

Fistula

*see also* Vascular access

a–v, blood flow, 686–687, 690–691

Cimino, thermography and, 272–276

use, 1978, 55

use, children 1978, 85–86

Foetal liver transplant in Fabry’s disease, 413–418

Frusemide

and gentamicin nephrotoxicity, 681–682

and peritoneum in dialysis, 155–164

Fuels and renal disease, 468–469

Fungal infection as cause of death 1978, 23–25

Gabexate mesilate and heparin in dialysis, 135–140

Galactose oxidase and neuraminidase, and memory cells, 437–441

Gammaglobulin, human and renal grafts, 426–430

Gastrin, pre-transplant, 400

Gentamicin nephrotoxicity, diuretics and, 681–682

Glomerular disease and toxic agents, 468–469, 473

Glomerulonephritis

complement and, 709–710

human membranous, and Heymann nephritis of rats, 706–708

mesangial IgA, 513–519

and HLA Bw35 antigen, 551–555

IgA, 513–519, 535–541, 551–555

immune complexes and, 709–710

circulating, 714–716

lymphocyte markers in, 714–716

mesangial, immunoglobulins and, 535–541

as primary renal disease, 1978, 19

in children, 84

recovery of renal function after, 43, 495–499

Glucocorticoids and phosphate wasting, 624–629

Glucose

*see also* Diabetes

levels and lipid disorders, 339

tolerance

in compensated renal failure, 703–705

haemodialysis patients, 698–699

haemofiltration patients, 698–699

ultrafiltration and dialysis, sequential, 698–699

Goodpasture’s syndrome, 520

plasma separation in, 528–534

as primary renal disease, 19

and recovery of renal function, 43

and toxic agents, 468

Gout

as primary renal disease, 19

and recovery of renal function, 43

Graft

donor kidneys, condition, 401–406

function, thermography to evaluate, 383–387

functioning, death with, 31–35

paired kidneys, fate of, 326–331

phosphate handling by, 624–629

second, 352–358

storage time before RT, 401–406

survival, 359–365

*see also* Blood group matching,

Blood transfusion, HLA matching, Immunosuppression, patient survival, presensitisation 1978, 37–41

and antibodies, 356

and azathioprine, 388–394

and blood transfusion, 297–304

by centre 1978, 72

'centre effect' and linear models, 318–325

children, 1978, 86–92

and cytotoxic antibodies before transplantation, 419–425

DLA tissue typing and, 366–371

donor dependence, 326–331

early graft loss, 356

and gammaglobulin, human, 426–430

HLA matching

*see* HLA matching

immunological and non-immunological, 347

and immunosuppression

*see* Immunosuppression

incompatibility, non–HLA, 301–302

and ischaemic time, 401–406

and Lewis blood group system, 377–382

760
Graft, survival (continued)
  longest, 72
  paired grafts compared, 326–331
  see also Patient survival
  regional variations, 318–325
  after re-transplantation, 347–358
  after re-transplantation, 1978, 40–41
  second graft, 352–358
  and suppression, immuno- and specific, 310–314, 315
  T cell levels pre-transplant and, 449–453
  third, surgery for, 357–358
Grafts for vascular access in HD
  see Vascular access

Growth
  children
    arrest and vitamin D, 644–648
    and CAPD, 190
    HD vs PD, 104
    long-term, 99
      under treatment 1978, 93–102, 104
      hormone, in compensated renal failure, 703–705

H₂ antagonists, post-transplant 1978, 63–64
Haemodialysers
  see Dialysers

Haemodialysis
  see also Dialysis
  aluminium and neurological disorders, 663–664
  amino acids in patients on, 129–134
  angiocardiographic studies in patients on, 244–251
  arteriovenous fistula, blood flow in, 690–691
  autonomic neuropathy and, 261–265
  blood pressure stability compared with haemofiltration, 695–697
  in children 1978, 85–86
  growth vs PD, 104
  duration of treatment and erythropoietin levels, 481–486
  and erythrocyte organic phosphates in uraemia, 723–724
  erythropoietin levels in patients on, 481–486
  fistula for
    see Fistula
  glucose tolerance in patients on, 698–699
  or haemofiltration, 218–224, 287
    blood pressure stability, 695–697
  or haemoperfusion, for peripheral neuritis, uraemic, 731–732
  hypertension in patients on, captopril for, 610–617

Haemodialysis (continued)
  HLA immunisation against in patients on, 372–375
  home, and CAPD, 284
  hormonal response to volume depletion in patients on, 252–260
  hospital, children, survival, 88
  membranes
    see Membranes, dialysis
    mitogen-induced lymphocyte transformation during, 711–713
    and neuropathy, short time, 729–730
    osteitis fibrosa in patients on, 675–676
    prolactin in patients on, 700–702
    residual renal function and requirements, 107–114
    for schizophrenia, 148–154, 683–685
    sexual activity in patients on, zinc and prolactin and, 661–662
    short time, and neuropathy, 729–730
    techniques 1978, 51–59
    tubing
      see Vascular access
    vascular access
      see Vascular access
    vasopressin response in patients on, 238–242
    water preparation 1978, 57–59

Haemodynamic
  dangers of high flow a–v fistulas, 686–687
  data on PTFE grafts for HD, 266–271
  studies
    in HD patients, 244–251
    in PD patients, 165–170

Haemofiltration
  blood pressure, stability during, 695–692
  in children 1978, 86
  clinical benefits, 218–224
  and erythrocyte organic phosphates in uraemia, 723–724
  glucose tolerance in patients on, 698–699
  or HD, 218–224, 287
  for residual renal function, 112
  high flux haemofiltrate, 695–697
  intestinal recycling of haemofiltrate and substitution in dogs, 205–211
  membranes for, SEDUFARK, 212–217
  peptide hormones and, 583–587
  vascular stability during, 695–697

Haemolytic uraemic syndrome, recovery of renal function after, 43, 495–499

Haemoperfusion
  bioincompatibility, 225–231
  vs. haemodialysis, for peripheral neuritis, uraemic, 731–732
  oxalate removal by, 717–718
  for peripheral neuritis, uraemic, 731–732
Haemoperfusion (continued)
  prostacyclin and, 225–231
Haemorrhage
  as cause of death 1978, 23–25
  and steroids, 400
Hand grip test and autonomic neuropathy,
  261–265
Heart
  see Cardiac
Henoch-Schönlein nephritis, HLA Bw35 and,
  555
Henoch-Schönlein purpura as primary renal
disease, 19
Heparin
  and gabexate mesilate in dialysis,
    135–140
  and prostacyclin in haemoperfusion,
    225–231
Hepatic necrosis and paracetamol, 473
Hepatitis
  1978, 63–67
  as cause of death 1978, 23–25
  and graft survival, 394
  immunisation against, 63, 66
  non-A, non-B, 141–147
Heredo-familial disease
  see Congenital disease
Herpes simplex, cellular immunity in, in RT
  patients, 745–746
Hexose monophosphate shunt, erythrocyte,
  in uraemia, 475–480
Heymann nephritis of rats and immune
  complexes, 706–708
High flux dialysers, 286–294
Histocompatibility testing
  see HLA matching
HLA
  immunisation against, in HD patients,
    372–375
  antigens, presensitisation, 419–425
  matching
    see also Graft survival,
    Immunosuppression, DLA matching
    A and B matching, 298–300, 302
    A9 and renal tract abnormalities, 549
    Bw35 antigen and mesangial IgA
glomerulonephritis, 551–555
    DR matching, 297–300
    and endothelial antibodies, 431–436
    and graft survival, 297–304,
      359–365
    and immunosuppression, 395–400
    and Lewis compatibility, 377–382
    and renal tract abnormalities,
      542–550
Home haemodialysis
  see Dialysis, home
Homograft
  see Graft
Hormone
  disturbances in chronic renal failure,
    703–705
  levels, plasma, in HD patients, 252–260
  natriuretic and prostaglandins, 577–582
  parathyroid
    see Parathyroid hormone
  peptide, renal handling and dialysis,
    583–587
Hormones and volume depletion in HD
  patients, 252–260
Hospitalisation 1978, 48–50
Human leucocyte antigen
  see HLA
Hydrochlorothiazide for renal hypercalciuria,
  571–576
Hypercalcaemic nephropathy as primary
  renal disease, 19
Hypercalciuria
  magnesium excretion in, 721–722
  stones, 563
  thiazide diuretics in, 571–576
Hyperkalaemia
  as cause of death 1978, 23–25, 29–31,
    70
  in children 1978, 86
Hyperlipidaemia, post-transplant,
  339–346
Hyperoxaluria
  oxalic acid concentration in, 566–570
  treatment, 569
Hyperparathyroidism
  see Parathyroid hormone, hyperpara-
  thyroidism
Hyperphosphataemia
  see Phosphate, hyperphosphataemia
Hypertension
  see also Blood pressure control
  in children after RT 1978, 97, 104
  converting-enzyme inhibitor to treat,
    603–609
  dialysis resistant, haemofiltration for,
    218–224
  in HD patients, captopril for, 610–617
  natriuresis of, 688–689
  and renal disease, 470, 472
  and residual renal function, 113
Hypertensive renal disease, prevention,
  469–470
Hypertriglyceridaemia
  see Triglycerides; Hypertriglyceridaemia
Hyponatraemia
  see Sodium; Hyponatraemia
Hyrophosphataemia
  see Phosphate; Hypophosphataemia
Hypoplasia, renal as primary renal disease in children 1978, 84
Hypotensive drugs and PTH, 649–655

Idiopathic anaphylactoid purpura, plasma exchange in, 520–527
IgA, etc.
see Immunoglobulins

Immune
complex disease, plasma exchange in, 520–527
complexes, circulating, in primary glomerulonephritis, 714–716
disease detection and, 709–710
and Heymann nephritis of rats, 706–708
mesangial, pathogenetic role, 535–541
response, modification, 305–317
system
see also Memory cells, Suppressor cells, T cells

Immunisation
anti-HLA in HD patients, 372–375
with gammaglobulin, human, post-transplant, 426–430

Immunoglobulins
and aminoglycosides, 597–602
IgA levels in Berger’s disease, 513–519
mesangial
IgA glomerulonephritis, 551–555
pathogenetic role, 535–541

Immunological
graft failure, 347
monitoring and renal transplantation, 442–448

Immunosuppression
see also Graft survival, HLA matching, Rejection, Specific suppression, Steroids
azathioprine with prednisolone for rejection, 395–400
before foetal liver transplant, 417–418
and graft survival, 305–317
and HLA matching, 395–400
post-transplant, and bone disease, 332–338
steroid, low dose for, 395–400

Immunosuppressive agents in renal cadaver grafting, 305–309

Impotence in dialysis patients, zinc and prolactin and, 661–662
Indomethacin and nephritis, 555

Infants
see also Children
screening for urinary infection, 459–461
Infarction as cause of death 1978, 23–25, 28, 70

Infection
see also Urinary infection, Viral infections as cause of death 1978, 23–25
Insulin
and CAPD, 184–188
in compensated renal failure, 703–705
renal handling and dialytic clearance, 583–587

Intellectual function and aluminium, 659–660, 663, 664
Irradiation, post-transplant 1978, 63–67
Ischaemic heart disease as cause of death 1978, 23–27
Ischaemic time and cadaver kidney function, 401–406

Isotopic clearance technique and oxalic acid concentration, 566–570

Keto-analogues, plasma, in uraemic patients, 719–720
Ketosis-susceptible diabetes see Diabetes

Kidney
see Graft, Renal machines
see Dialysers stones
see Stones

Kidneys
cadaver
for re-transplantation, 347
storage, function, 401–406

Leucocyte transfusion and graft survival, 366–371
Lewis blood group system
matching and graft survival, 301
and renal transplantation, 377–382
Linear models and graft survival, 318–325

Lipid
changes, hyperlipidaemia post-transplant, 339–346
pattern and dialysate, 115–121

Lipids
see also Triglycerides
and anticoagulants in dialysis, 135–140
Lithium nephropathy, 467–468, 471
Liver
disease as cause of death 1978, 23–25
necrosis and paracetamol, 473
transplantation, foetal, and Fabry’s disease, 413–418
Lupus
erythematous as primary renal disease, 19
Lupus (continued)
erythematous and recovery of function, 43
nephritis, recovery of renal function after, 495–499

Lymphocyte
antigen, human see HLA
markers in primary glomerulonephritis, 714–716
transformation during HD mitogen-induced, 711–713

Lysozyme and aminoglycosides, 597–602

Magnesium
in chronic renal failure patients, 665–667
excretion in hypercalciuria, 721–722

Malignant disease
and analgesic nephropathy, 467
as cause of death 1978, 23–27, 29, 70
dialysis and transplantation patients, 1978, 18, 20
immunosuppressive therapy and, as cause of death 1978, 23–25
as primary renal disease, 19
recovery of renal function, 43
renal, detection, 474
renal pelvic carcinoma and analgesic nephropathy, 467

Malnutrition in uraemic patients, 129–134

Maturation
see Growth

Meat, cooked and raw, creatinine levels, 506–512

Medical staff, provision, children, 81

Medullary cystic disease as primary renal disease, 19

Membranes
dialysis
cellulose, rejection characteristics and solute permeability, 198–204
Cuprophan PM 150, 198–204
and HD, 286–294
high flux, 198–204, 212–217
and insulin clearance, 583–587
and middle molecules in residual renal function, 113
and peptide clearance, 583–687
polycrylonitrile (PAN), 212–217
and schizophrenia, 154, 683–685
transport theory, 286–287
haemofiltration, SEDUFARK, 212–217

Memory cells
detection, 437–441

Menarche, age at onset 1978, 102

Mental disorders
see Schizophrenia

Mental function
and aluminium 659–660
in dialysis patients, 663–664
D-3-mercapto-2-methylpropanoyl-L-proline see Captopril

Mesangial
IgA glomerulonephritis and HLA Bw35 antigen, 551–555
immune deposits, pathogenetic role, 535–541

Mesothelium and dialysis, 155–164

Metoprolol
and calcitonin concentrations in uraemic patients, 649–655
and parathyroid hormone concentration in uraemic patients, 649–655

Methyldopa and hepatitis, 146

Methylprednisolone
see Steroids

β-2 microglobulin and aminoglycosides, 597–602

Middle
molecule hypothesis and dialysis membranes, 289–291
molecules, dialysis index for, 107–114

Mineral metabolism after renal transplantation, 618–623

Mitogen-induced lymphocyte transformation during HD, 711–713

Mortality
see Death rates

Motor nerve conduction velocity and residual renal function, 107–114

Multi-system disease
as primary renal disease 1978, 18
and recovery of function, 43

Musculo-skeletal complications of renal transplantation, 332–338

Myasthenia gravis, plasma exchange for, 533

Myeloma
multiple, plasma separation in, 528–534
recovery of renal function, 495–499

Myelomatisis
as primary renal disease, 19
and recovery of function, 43

Myocardial
see also Cardiac
ischaemia as cause of death 1978, 23–28, 70

Myocardium in HD patients, 244–251

Nandrolone and hepatitis, 144

Natriuresis
see Sodium excretion

Natriuretic hormones, action and prostaglandins, 577–582
Necrograft  
see Graft

Necrosis  
see Aseptic necrosis, Avascular necrosis of bone, Cortical necrosis, Femoral head necrosis, Hepatic necrosis, Tubular necrosis

Needles, dialysis  
see Fistula, Vascular access

Neonates, screening for urinary infection, 459

Neoplasms  
see Malignant disease

Nephritides  
see also Glomerulonephritis, Henoch-Schönlein nephritis, Heymann nephritis, Pyelonephritis  
as primary renal disease 1978, 18  
and recovery of function, 43

Nephrocalcinosis and recovery of renal function, 43

Nephrolithiasis, calcareous, in hypercalciuria, 721–722

Nephropathy  
see Renal disease

Nephrotic syndrome, platelet hypersensitivity in, 487–495

Nephrotoxicity  
see Toxic agents, Drug toxicity, Drug nephropathy

Neuraminidase and galactose oxidase and memory cells, 437–441

Neuritis, peripheral uraemic haemoperfusion for 731–732

Neurological abnormalities and aluminium in dialysis patients, 663–664

Neuropathy  
autonomic, 261–265  
and haemofiltration, 218–224  
and residual renal function, 107–114  
and short-time haemodialysis, 729–730

Neutron activation analysis, trace elements studied with, 665–667

Nitroprusside and peritoneum in dialysis, 155–164

Nutrition in uraemic patients, amino acids in, 129–134

Osteomalacia, aluminium and, 588–596

Oxalate  
and hyperoxaluria, 566–570  
removal by dialysis and haemoperfusion, 717–718  
in urinary stone disease, 563–564

Oxalic acid concentration, 566–570

Oxalosis  
adult primary, pyridoxine therapy for, 727–728  
as primary renal disease, 19

Oxygen delivery and renal disease, 115–121

Paediatric patients  
see Children

Paediatrician in centres 1978, 81

Pancreatic islet transplantation, 418

Pancreatitis  
as cause of death 1978, 23–25  
trypsin to diagnose in renal disease, 725–726

Paper selection, EDTA conference, 747–752

Paracetamol as cause of analgesic nephropathy, 467, 472–473

Parathyroid hormone  
and aluminium, 594  
and autonomic neuropathy, 265  
and avascular necrosis of bone, 333, 337  
and CAPD, 192  
concentrations in uraemic patients, propranolol and metoprolol and, 649–655  
and haemofiltration, 218–224  
hyperfunction, thiazide diuretics for, 571–576

Hyperparathyroidism  
and phosphate handling after RT, 624–629  
post-transplant, and calcium, 677–678  
vitamin D and, in children, 644–648  
and hypophosphataemia, 618–623  
vasodepressive effect post-transplant, 679–680  
and vitamin D, 637–644

Passive enhancement  
see Antibody-induced suppression

Patient selection children, 104

survival  
see also Graft survival 1978, 36–37  
and centre activity, 72  
children 1978, 86–92  
after re-transplantation, 352

Penicillins and aminoglycosides, proteinuria and, 597–602

Pentagastrin pre-transplant, 400
Phosphate (continued)
clearance, dialysis membranes, 292
hyperphosphataemia
and haemofiltration, 218–224
vitamin D metabolites and, 675–676
phosphate wasting in transplanted
kidney, 624–629
hypophosphataemia, pathogenesis and
RT, 618–623
and transplanted kidney, 624–629
and vitamin D, 625, 637–644
in children, 647
Phosphates
erthrocyte organic, in uraemia, 723–724
Phototherapy, ultraviolet, in uraemic pruritus,
743–744
Physicians and urinary tract stone disease,
556–565
Piretanide, 681–682
Pituitary gonadal axis in compensated renal
failure, 703–705
Plasma
exchange
for anti-GBM antibody-mediated
disease, 533
in immune complex disease, 520–527
separation in Goodpasture's syndrome
and multiple myeloma, 528–534
Plasticisers
and liver in uraemia, 232–237
migration from PVC HD tubes, 739–740
Platelet hypersensitivity in nephrotic
syndrome, 487–495
Polyarteritis and recovery of renal function,
43
Polycystic kidneys
see Cystic kidney disease
Polyneuropathy, haemofiltration for,
218–224
Polytetrafluoroethylene grafts for HD,
haemodynamic data, 266–271
Poster selection, EDTA conference, 747–752
Potassium in peritoneum in dialysis, 155–164
Prednisolone
with azathioprine for rejection, 395–400
for rejection, 388–394
Prednisone
see also Steroids
and lipid disorders, 339, 342
and rejection crises, 364
Pregnancies 1978, 43–44
Pregnancy sera for gammaglobulin, human,
426–430
Presensitisation and graft survival, 347,
419–425
Primary renal disease 1978, 15
Programme selection, EDTA conference,
747–752

C-peptide in compensated renal failure,
703–705
Peptide hormones, renal handling and dialysis,
583–587
Pericarditis, haemorrhagic as cause of death
1978, 23–25
Piretanide and gentamicin nephrotoxicity,
681–682
Peripheral neuritis, uraemic, haemoperfusion
for, 731–732
Peritoneal dialysis
see also Dialysis
children 1978, 86
growth vs HD, 104
chronic intermittent, residual peritoneal
fluid, biochemical measurements for,
737–738
continuous ambulatory, 178–183
bilateral nephrectomy patients and,
192
for children, 178, 183
for diabetics with renal failure,
184–189, 190
for end stage renal failure, 171–177
and home haemodialysis, 284
and intermittent compared, 171–177
peritonitis in, see Peritonitis
residual renal function and, 113
survey, 281–285
death, causes 1978, 61
in diabetes, ketosis-susceptible, 735–736
efficiency, 280–281
general survey, 277–285
haemodynamics in, 165–170
home or hospital, 70
intermittent and continuous ambulatory
compared, 171–177
residual renal function and, 113
solute transport, 277–279
survival rates 1978, 61–62
techniques 1978, 59–60
and transplantation, 71
Peritoneal fluid, residual, in PD, biochemical
measurements, 737–738
Peritoneal microcirculation, 279–280
Peritoneum, parietal, and dialysis, 155–164
Peritonitis
and continuous ambulatory peritoneal
dialysis, 171–177, 180–181, 183
in CAPD, avoidance, 733–734
in diabetics on CAPD, 188
and peritoneal dialysis, 70
Phenacetin-induced nephropathy, 466–468,
474
Phosphatase, alkaline, and vitamin D,
637–644
Phosphate
binders, aluminium containing, 588–596

766
Prolactin
in compensated renal failure, 703–705
in renal failure, HD and RT patients, 700–702
and sexual activity in HD patients, 661–662
Propranolol
and calcitonin concentrations in uraemic patients, 649–655
and parathyroid hormone concentration in uraemic patients, 649–655
and uraemic osteodystrophy, 668–671
Prostacyclin and charcoal haemoperfusion, 225–231
Prostaglandins and natriuretic hormone in rat kidneys, 577–582
Protein
intracellular free amino acids in HD patients, 129–134
losses and CAPD, 190
and urinary calcium excretion, 564
Proteins, low molecular weight, in aminoglycoside nephrotoxicity, 597–602
Proteinuria
aminoglycosides and, 597–602
cephalosporins and 597–602
penicillin and, 597–602
Pruritis, uraemic ultraviolet phototherapy in, 743–744
Psychologist in centres for children 1978, 81
PTFE grafts for HD, use 1978, 55
haemodynamic data, 266–271
Puberty, onset of 1978, 102
Pulmonary
artery pressure in PD patients, 165–170
infection as cause of death 1978, 23–25
PVC tubing, migration of plasticisers from, 739–740
Pyelonephritis
chronic
pathogenesis, 458–459, 471, 473
prevention, 457–463, 470–471
as primary renal disease 1978, 18
in children 1978, 84
recovery of renal function after, 495–499
tissue typing, 542–550
Pyridoxine
and amino acid balance in uraemic patients, 134
in hyperoxaluria, 569
therapy, oxalosis, adult primary, 727–728

Reflux
renal
in adults, 470–471
and chronic pyelonephritis, 450–459, 473, 474
familial, 542–550
post-transplant, 474
vesico-ureteric, 542–550
and chronic pyelonephritis, 458–459, 473
treatment, 463
Refusal of treatment as cause of death 1978, 23–25
Registry (EDTA) statistics 1978, 2–104
Regular dialysis treatment
see Dialysis, Haemodialysis
Rehabilitation
see also Bone disease, renal
1978, 44–48
children, 92–93
Rejection
cries, 359–365
of graft
see also Graft survival,
Immunosuppression
azathioprine or cyclophosphamide
for, 388–394
children 1978, 86, 98
and Lewis compatibility, 382
prednisolone for, 388–394
and steroid, low dose, 395–400
thermography to detect, 383–387
endothelial antibodies and, 431–436
specific suppression, 310–314
suppressor cells, donor specific and,
442–448
Renal
amyloidosis
see Amyloidosis
artery stenosis, surgery for, 469, 473
atrophy, familial, 542–550
bone disease
see Bone disease, renal
duplex systems familial, 542–550
disease
activity, immune complexes and complement breakdown products to
detect, 709–710
drug nephropathies, 466–468, 474
hypertensive, prevention, 469–470
prevention, 466–474
primary 1978, 15
children, 84
failure
acute, prolonged, recovery after,
495–499
aluminium accumulation in, 588–596
Renal (continued)

failure (continued)

amyloidosis caused by, dimethylsulphoxide to treat, 500–505
chronic
in children, vitamin D for bone
disease in, 644–648
erythrocyte organic phosphates in,
723–724
hormonal disturbances in, 703–705
prevention, 457–474
as primary renal disease 1978, 18
prolactin in patients in, 700–702
trace elements in patients with,
665–667
tryptsin concentration in pancreatitis
in, 725–726
vitamin D metabolism and bone
disease in, 630–636, 644–648
function
and dislipaemia, post-transplant,
339–346
recovery 1978, 41–43
after acute renal failure, 495–499
residual see Residual renal function

graft
see Graft
hypercalciuria
see Hypercalciuria
osteo dystrophy
see Bone disease, renal
pelvic carcinoma and analgesic
nephropathy, 467
reflux
see Reflux, renal
scarring and chronic pyelonephritis,
458–459
familial, 542–550
stones
see Stones
tract abnormalities familial, 542–550
transplantation
see Transplantation, renal
tumour
and analgesic nephropathy, 467
detection, 474
and recovery of renal function, 43
vascular disease
see Vascular disease, renal
vein thrombosis, 473

Residual renal function
and captopril, 614
and dialysis membranes, 291–292
dialysis requirements, 107–114
Re-transplantation, value, 347–351,
351–358
Rhesus matching and graft survival, 301
Rickets and vitamin D, 633

Salt
intake
see also Sodium
and captopril, 610–617
subtraction for hypertension in HD
patients, 610–617
Saphenous grafts, thermography and,
272–276
Scarring, renal
see Renal scarring
Schizophrenia, HD for, 148–154, 683–685
School
children
see Children
hospital, in centres for children 1978, 81
Scleroderma
as primary renal disease, 19
and recovery of function, 43
Screening for urinary infection, 459–463
Second transplant
see Transplantation, renal,
Re-transplantation
SEDUFARK and haemofiltration, 212–217
Selection of patients, children, 1978, 104
Selective dual filtration artificial kidney
(SEDUFARK), 212–217
Septicaemia as cause of death 1978, 23–25
Sexual activity in dialysis patients, zinc and
prolactin and, 661–662
Shunt
see Vascular access
Sight, impaired, and CAPD, 184, 185
Single needle technique
see Vascular access
Skeletal
maturation
see also Growth
children on dialysis 1978, 93–95, 102
mineralisation and vitamin D metabolites,
633
Skin disorders in RT patients, long-term,
741–742
Social worker in centres for children 1978, 81
Sodium
excretion and hypertension, 688–689
hyponatraemia and hypertension in HD
patients, 610–617
natriuretic hormone and prostaglandins,
577–582
in peritonema in dialysis, 155–164
Solvents, organic and renal disease, 468–469,
472
Specific suppression of rejection in RT,
310–314
Speech disorders and dialysis encephalopathy,
659–660
Spina bifida as primary renal disease in
children 1978, 85
Staff, medical, provision, children, 81
Statistics, registry (EDTA) 1978, 2–104
Steroids
see also Growth, Immunosuppression and aluminium, 412
before foetal liver transplant, 417
and growth of children after RT 1978, 95–102
and lipid disorders, 339, 342
low dose from day after RT, 395–400
plasma exchange and 520–527
post-transplant 1978, 63–64, 72, 73
bone disease, 332–338
and rejection, 388–394
cries, 365
Stones
see also Hypercalciuria, Oxalosis
urinary tract
causes, 564
non-surgical treatment, 556–565
pathogenesis, 558
treatment, 560–562
types, 557–558
Suicide
in patients 1978, 23–27, 29–31
and other chronic diseases, 70
Sulphaemoglobin production in uraemia, 475–480
Suppression
see Immunosuppression, Specific
suppression, Antibody-induced suppression
Suppressor cells, donor specific, and rejection, 442–448
Surgery, recovery of donor function after, 495–499
Surgical loss and recovery of renal function, 43
Survival
see also Graft survival, Patient survival
1978, 22–35, 71, 72
children 1978, 86–92
Systemic lupus erythematosus, plasma exchange in, 520–527

T cells
cytolytic and memory cells, 437–441
pre-transplant, and graft survival, 449–453
Thermography
in renal transplantation, 383–387
for vascular access survey in HD, 272–276
Thiamine in hyperoxaluria, 569
Thiazide diuretics in renal hypercalciuria, 571–576
Third graft
see Transplantation, renal, Re-transplantation

Thoracic duct drainage, post-transplant 1978, 63–64
Thrombosis
 coronary as cause of death 1978, 23–25, 71
and platelet sensitivity, 487–495
Thyrotropin in compensated renal failure, 703–705
Tissue typing
see HLA matching, DLA matching
Tobramycin
see aminoglycosides
Toxic agents
see also Drug nephropathy, Drug toxicity
and renal disease, 468–469, 472
Trace elements in chronic renal failure
patients, 665–667
Transfer of patients 1978, 5, 72
Transfusion
see Blood transfusion, Erythrocyte transfusion, Leucocyte transfusion, Plasma exchange
Transplant
see Graft
Transplantation
see Foetal liver transplant
foetal liver in Fabry’s disease, 413–418
pancreatic islet, 418
renal
age of patients 1978, 9
antibodies, endothelial, in, 431–436
autonomic neuropathy and, 261–265
blood pressure regulation after, PTH and, 679–680
for CAPD patients, 192–193
centres,
activity 1978, 9
variations in success, 318–325
children, death rates 1978, 86–92
cytomegalovirus infection, cellular immunity and, after, 745–746
cytotoxic antibodies before and, 419–425
dermatological findings, long-term, after, 741–742
and dialysis dementia, 407–412
dialysis, time on, before, 400
graft
see Graft
growth of children after, 1978, 95–102
H₂ receptor blocking drugs pre-transplant, 400
herpes simplex infection, cellular immunity and, after, 745–746
high risk patients, 400
hyperlipidaemia after, 339–346
hypophosphataemia after, 618–623

769
Transplantation (continued)
renal (continued)

immunosuppression
see Immunosuppression
Lewis blood group system and,
377–382
lipid changes after 339–346
longest survival after, 72
management 1978, 62–63
mineral metabolism after, 618–627
orthopaedic complications, 332–338
parathyroid hormone and blood
pressure regulation after, 679–680
patient survival
see Patient survival
phosphate handling after, 624–629
prolactin levels after, 700–702
recovery of orginal function after,
1978, 41–43
rejection
see Rejection
re-transplantation, 353–358
steroid, low dose, from day after,
395–400
storage of kidneys before, 401–406
T cell levels and graft survival,
449–453
thermography in, 383–387
virus infections, cellular immunity and,
after, 745–746

Traumatic loss and recovery of renal function, 43

TRH and prolactin, 700–702

Tricoire thermography in RT, 383–387

Triglycerides
see also Lipids
hypertriglyceridaemia
and continuous ambulatory peritoneal
dialysis, 179, 182–183
haemofiltration for, 218–224
in uraemic patients, 115–121

Trypsin, concentration in renal disease,
725–726

Tuberculosis
as cause of death 1978, 23–25
as primary renal disease, 19
and recovery of renal function, 43

Tubular necrosis
as primary renal disease in children 1978,
84
recovery of renal function after, 498

Tumours
see Malignant disease

Ultrafiltration
see also Haemofiltration
in children 1978, 86

Ultrafiltration (continued)
control and dialysis, 288–289
and dialysis, glucose tolerance in patients
on, 698–699
hormonal response to volume depletion
by, 252–260
in peritoneal dialysis, 165–170

Ultraviolet phototherapy in uraemic pruritis,
743–744

Uraemia
see also Renal disease, chronic
amino acid abnormalities and, 129–134
chronic, membranes, HD and, 286–294
in diabetics on CAPD, 189
erythropoietin levels in, 481–486
graft failure caused by, as cause of death,
1978, 23–25
hepatitis, new strain in, 141–147
hypertriglyceridaemia and dialysate in,
115–121
keto-analogues in, 719–720
liver and plasticisers, 232–237
sulphhaemoglobin production in, 475
475–480
neuropathy
see Neuropathy, uraemic
plasma toxicity, 217

Ureteroceles familial, 542–550

Urinary
infection
and chronic pyelonephritis, 458–459
screening of children for, 459–462
screening of adults for, 462–463
treatment, 464–471
tract
abnormalities, 542–550
stone disease
see Stones, urinary tract

Valsalva ratio and autonomic neuropathy,
261–265

Vascular
access
1978, 53–57
angiography to survey, 272–276
children 1978, 85
fistula
see Fistula
grafts, percentage use 1978, 55
grafts, PTFE, haemodynamics,
266–271
shunts
children 1978, 85
percentage use, 55
single needle technique 1978, 56–57
children 1978, 85–86
thermography to survey, 272–276

770
Vascular (continued)
  access (continued)
    tubing, PVC, migration of plasticisers from, 739–740
  disease, renal
    as primary renal disease 1978, 18
    as primary renal disease in children 1978, 84
    and recovery of renal function, 43
    permeability and immune complexes, 706–708
    stability
      see Blood pressure, control
Vasopressin
  see also Blood pressure, control
  concentration in HD patients, 252–260
  response in HD patients, 238–242
Vasodepressive effect of PTH, post-transplant, 679–680
Vein access
  see Vascular access
Vesico-ureteric reflux
  see Reflux, vesico-ureteric
Viral infection
  as cause of death 1978, 23–25
  cellular immunity and, in RT patients, 745–746
Visual problems and diabetics on CAPD, 184, 185
Vitamin B₁₂, clearance and dialysis membranes, 293
Vitamin D
  analogues and renal bone disease, 637–644
  metabolism and bone disease in chronic renal failure, 630–636
  metabolites
    and hypophosphataemia, 618–623, 624–629
    and osteitis fibrosa in HD patients, 675–676
  for renal bone disease in children, 644–648
Volume depletion, hormonal response to, in HD patients, 252–260
  Water preparation in haemodialysis 1978, 57–59
  Wearable filtration artificial kidney (WFAK), 205–211
  Women, screening for urinary infection, 462–463
X-ray therapy, post-transplant 1978, 63–67
Zinc
  in chronic renal failure patients, 665–667
  and sexual activity in dialysis patients, 661–662